Article

Cancer Survivors Face Tougher Road to Access Health Care in Non-Expansion States

Study finds greater access to Medicaid needed for low income cancer survivors.

In a published analysis, investigators found that cancer survivors were less likely to have a personal doctor, annual checkups, and accessibility to health care services in states that do not have expanded Medicaid.

Due to the high cost of treatment, currently cancer survivors are frequently unable to see a doctor, which also held true in the era prior to the passage of the Affordable Care Act (odds ratios 0.76 and 1.14).

"Populations most affected are the low-income and uninsured,” said study author Cathy J. Bradley, PhD. “If cancer survivors cannot get the follow-up care they need, recurrences may be missed and long-term consequences of cancer treatment may not be appropriately managed."

Since most cancer survivors are high risk for developing other types of cancers, investigators found that it would be much more beneficial for low-income survivors if there was an increased availability to Medicaid.

Although the reasons for the differences in the study were outside their scope, researchers assume that non-expansion states have greater rates of uninsured individuals and stricter criteria for eligibility in the Medicaid programs already in place.

Related Videos
Anthony Perissinotti, PharmD, BCOP, discusses unmet needs and trends in managing chronic lymphocytic leukemia (CLL), with an emphasis on the pivotal role pharmacists play in supporting medication adherence and treatment decisions.
Image Credit: © alenamozhjer - stock.adobe.com
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix
pharmacogenetics challenges, inter-organizational collaboration, dpyd genotype, NCCN guidelines, meta census platform, evidence submission, consensus statements, clinical implementation, pharmacotherapy improvement, collaborative research, pharmacist role, pharmacokinetics focus, clinical topics, genotype-guided therapy, critical thought
Image Credit: © Andrey Popov - stock.adobe.com
Image Credit: © peopleimages.com - stock.adobe.com
TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC
World Standards Week 2024: US Pharmacopeia’s Achievements and Future Focus in Pharmacy Standards